ClinicalTrials.gg
TerminatedNCT03819218Updated Mar 19, 2021Results posted

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects

A Phase 2 interventional study of MC2-01 cream in Psoriasis Vulgaris, sponsored by MC2 Therapeutics. Terminated at 2 sites in 2 countries. Open to participants aged 12 Years to 16 Years. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by MC2 Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
12 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
43rd of 47
7 · median 200
Started
2018
with 2 others
Phase 2
9 of 47
none open now
Registered
37th of 47
by date
Lead sponsor
4 of 47
MC2 Therapeutics

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 43rd largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 2, and was the 37th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

This is a phase 2, open-label, single-group, multicentre trial in which the investigational product, MC2-01 cream, is investigated in adolescent subjects (age 12 to 16 years, 11 months) with clinically diagnosed extensive psoriasis vulgaris.

Read the detailed description

The MC2-01 cream is designed for optimal patient satisfaction - it quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on with daily routines. In this trial, subjects who fulfil all inclusion and exclusion criteria are enrolled in the trial and will apply one dose of trial medication topically once daily for 8 weeks. The purpose of the trial, is to determine the and pharmacokinetic parameters of MC2-01 cream in adolescent subjects under maximum use conditions.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The parent(s), or legal guardian(s) (according to national law) have provided written following their receipt of verbal and written information about the trial
  • The subject (according to national law) has provided written assent to the trial following their receipt of verbal and written information about the trial
  • Generally healthy males or non-pregnant females, of any race or ethnicity, who are between 12 to 16 years, 11-month-old at Screening Visit 1 (SV1)
  • At Visit 1/Day 0, have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6 months duration involving body (trunk and/or limbs), with or without scalp
  • Have a treatment area between 10% and 30% of the Body Surface Area (BSA) on the body (trunk and/or limbs) and scalp, excluding psoriatic lesions on the face, genitals, and intertriginous areas, at Visit 1/Day 0
  • Have a Physician's Global Assessment (PGA) of at least moderate severity on the treatment area
  • A normal HPA axis function including a serum cortisol concentration above 4,5 mcg/dl before ACTH-challenge and equal or above 18 mcg/dl 30 minutes after ACTH challenge, at Screening Visit 2 (SV2)
  • A serum albumin-corrected calcium below the upper reference limit at SV2

Exclusion criteria

Exclusion Criteria:

  • Have a current diagnosis of unstable forms of psoriasis, including erythrodermic or pustular psoriasis
  • Other inflammatory skin disease in the treatment area that may confound the evaluation of the psoriasis vulgaris
  • Presence of infections in the treatment area or skin manifestations or atrophic skin, atrophic striae, skin vein fragility, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wounds in the treatment area
  • Presence of pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment areas, which could interfere with the rating of efficacy parameters
  • Planned excessive or prolonged exposure to either natural or artificial sunlight
  • Use of phototherapy (psoralen + ultraviolet A radiation and ultraviolet B radiation within 4 weeks prior to SV2 and during the trial
  • Current or past history of disorders of calcium metabolism associated with hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders
  • Oral calcium supplements, vitamin D supplements, bisphosphonates or calcitonin within 4 weeks prior to SV2
  • Planned initiation of, or changes to concomitant medication that could affect calcium metabolism during the trial;
  • Planned initiation of, or changes to, concomitant estrogen therapy during the trial
  • Strong systemic cytochrome P450 3A4 (CYP 3A4) inhibitors or inducers within 4 weeks prior to SV2 and during the trial
  • Use of topical treatments, except for emollients and non-medicated shampoos, with a possible effect on psoriasis within 2 weeks prior to SV2 and during the trial
  • Systemic treatment with biological therapies, with a possible effect on psoriasis vulgaris within the following time period prior to SV2 and during the trial
  • Initiation of, or expected changes to, concomitant medication that may affect psoriasis during the trial
  • Any of the following conditions, whether known or suspected; Clinically diagnosed depression where the subject is in current treatment with medication approved for treatment of depression; Endocrine disorders known to affect cortisol levels or HPA axis integrity; Non-nocturnal sleep patterns
  • Use of systemic medication that suppresses the immune system and other systemic chemotherapeutic antineoplastic therapy within 4 weeks prior to the SV2 and during the trial
  • Use of 4 weeks before SV2 and during the trial
  • Have clinical signs of skin infection with bacteria, viruses, or fungi
  • Known (HIV) infection, active or
  • Known or suspected of to any component of the test product
  • Known allergic asthma, serious allergies or allergies where recurrent acute or chronic treatment is necessary
  • Have any chronic or acute medical condition that, in the opinion of the investigator, may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial
  • Require the use of any concomitant medication that, in the investigator's opinion, has the potential to cause an adverse effect when given with the Product (IP) or will interfere with the interpretation of the trial results
  • Subject with known abnormal reduction in muscle mass, as judged by the investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    MC2-01 cream

    MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks

    Drug: MC2-01 cream

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 4

    Adrenal function will be assessed in a challenge test with an intravenous dose of cosyntropin. Measurement of serum cortisol levels pre- and post- stimulation is an accepted standard method used to evaluate adrenal suppression. The test consists of an initial blood sampling. Following the blood sample, an intravenous bolus injection of 0.25 mg cosyntropin is given. The serum cortisol concentration 30 min. after will reflect stimulation of the adrenal glands induced by cosyntropin. HPA axis suppression is define as serum cortisol below 18 µg/dL

    Time frame: Week 4

  2. Number of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 8

    Adrenal function will be assessed in a challenge test with an intravenous dose of cosyntropin. Measurement of serum cortisol levels pre- and post- stimulation is an accepted standard method used to evaluate adrenal suppression. The test consists of an initial blood sampling. Following the blood sample, an intravenous bolus injection of 0.25 mg cosyntropin is given. The serum cortisol concentration 30 min. after will reflect stimulation of the adrenal glands induced by cosyntropin. HPA axis suppression is define as serum cortisol below 18 µg/dL

    Time frame: Week 8

  3. Change in S-Calcium Metabolism at Week 4

    Change from Baseline to Week 4 in albumin-corrected S-calcium

    Time frame: Week 4

  4. Change in S-Calcium Metabolism at Week 8

    Change from Baseline to Week 8 in albumin-corrected S-calcium

    Time frame: Week 8

  5. Change in U-Calcium Metabolism at Week 4

    Change from Baseline to Week 4 in Urinary Calcium/Creatinine ratio (mol/mol)

    Time frame: Week 4

  6. Change in U-Calcium Metabolism at Week 8

    Change from Baseline to Week 8 in Urinary Calcium/Creatinine ratio (mol/mol)

    Time frame: Week 8

Secondary outcomes

  1. The Maximum Plasma Concentration [Cmax] of Betamethasone 17-propionate at Week 4

    The Maximum Plasma Concentration \[Cmax\] of the metabolite of BDP, betamethasone 17-propionate measured at Week 4.

    Time frame: Week 4

  2. Time to Maximum Plasma Drug Concentration [Tmax] of Betamethasone 17-propionate at Week 4

    Time to maximum plasma drug concentration \[Tmax\] of the metabolite of BDP, betamethasone 17-propionate measured at Week 4.

    Time frame: Week 4

07

Results

Posted Feb 21, 2021

Participant flow

Participant flow — Overall Study
MilestoneMC2-01 Cream
Started7
Completed6
Not completed1
Withdrew: Protocol violation1

Outcome measures

PrimaryNumber of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 4

Adrenal function will be assessed in a challenge test with an intravenous dose of cosyntropin. Measurement of serum cortisol levels pre- and post- stimulation is an accepted standard method used to evaluate adrenal suppression. The test consists of an initial blood sampling. Following the blood sample, an intravenous bolus injection of 0.25 mg cosyntropin is given. The serum cortisol concentration 30 min. after will reflect stimulation of the adrenal glands induced by cosyntropin. HPA axis suppression is define as serum cortisol below 18 µg/dL

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 4
ParticipantsMC2-01 Cream
Number of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 40
PrimaryNumber of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 8

Adrenal function will be assessed in a challenge test with an intravenous dose of cosyntropin. Measurement of serum cortisol levels pre- and post- stimulation is an accepted standard method used to evaluate adrenal suppression. The test consists of an initial blood sampling. Following the blood sample, an intravenous bolus injection of 0.25 mg cosyntropin is given. The serum cortisol concentration 30 min. after will reflect stimulation of the adrenal glands induced by cosyntropin. HPA axis suppression is define as serum cortisol below 18 µg/dL

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 8
ParticipantsMC2-01 Cream
Number of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 80
PrimaryChange in S-Calcium Metabolism at Week 4

Change from Baseline to Week 4 in albumin-corrected S-calcium

Time frame:
Week 4
Reported as:
Mean · mmol/L
Change in S-Calcium Metabolism at Week 4
mmol/LMC2-01 Cream
Change in S-Calcium Metabolism at Week 4-0.037 ± 0.084
PrimaryChange in S-Calcium Metabolism at Week 8

Change from Baseline to Week 8 in albumin-corrected S-calcium

Time frame:
Week 8
Reported as:
Mean · mmol/L
Change in S-Calcium Metabolism at Week 8
mmol/LMC2-01 Cream
Change in S-Calcium Metabolism at Week 8-0.027 ± 0.060
PrimaryChange in U-Calcium Metabolism at Week 4

Change from Baseline to Week 4 in Urinary Calcium/Creatinine ratio (mol/mol)

Time frame:
Week 4
Reported as:
Mean · mol/mol
Change in U-Calcium Metabolism at Week 4
mol/molMC2-01 Cream
Change in U-Calcium Metabolism at Week 40.115 ± 0.426
PrimaryChange in U-Calcium Metabolism at Week 8

Change from Baseline to Week 8 in Urinary Calcium/Creatinine ratio (mol/mol)

Time frame:
Week 8
Reported as:
Mean · mol/mol
Change in U-Calcium Metabolism at Week 8
mol/molMC2-01 Cream
Change in U-Calcium Metabolism at Week 80.058 ± 0,186
SecondaryThe Maximum Plasma Concentration [Cmax] of Betamethasone 17-propionate at Week 4

The Maximum Plasma Concentration \[Cmax\] of the metabolite of BDP, betamethasone 17-propionate measured at Week 4.

Time frame:
Week 4
Reported as:
Mean · pg/mL
The Maximum Plasma Concentration [Cmax] of Betamethasone 17-propionate at Week 4
pg/mLMC2-01 Cream
The Maximum Plasma Concentration [Cmax] of Betamethasone 17-propionate at Week 437.53 ± 22.82
SecondaryTime to Maximum Plasma Drug Concentration [Tmax] of Betamethasone 17-propionate at Week 4

Time to maximum plasma drug concentration \[Tmax\] of the metabolite of BDP, betamethasone 17-propionate measured at Week 4.

Time frame:
Week 4
Reported as:
Mean · Hours
Time to Maximum Plasma Drug Concentration [Tmax] of Betamethasone 17-propionate at Week 4
HoursMC2-01 Cream
Time to Maximum Plasma Drug Concentration [Tmax] of Betamethasone 17-propionate at Week 42.333 ± 1.155

Adverse events

Collected over AEs were collected/assessed from the time of the signature of the informed consent form by the participant and until the final follow-up visit has occurred, i.e. up to in total up to 18 weeks, including a screening period of up to 6 weeks, a treatment period of 8 weeks and a follow-up period of 4 weeks. AEs that were considered related to the trial product would be followed until they were resolved, or until the medical condition of the participant was stable.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MC2-01 Cream0/7 (0%)0/7 (0%)3/7 (42.9%)
Most frequent other events
Most frequent other events
EventMC2-01 Cream
NasopharyngitisInfections and infestations1/7
TonsillitisInfections and infestations1/7
DysuriaRenal and urinary disorders1/7
AcneSkin and subcutaneous tissue disorders1/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)MC2-01 Cream
Mean14.7 ± 1.4
Sex: Female, Male
Sex: Female, Male(Participants)MC2-01 Cream
Female3
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MC2-01 Cream
Hispanic or Latino0
Not Hispanic or Latino7
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MC2-01 Cream
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)MC2-01 Cream
Czechia5
Germany2
08

Study locations

2 sites
  • PRO SANUM a.s.
    Prague, 110 00, Czechia
  • Dept. of Dermatology, Venereology and Allergology
    Frankfurt, Frankfurt/Main 60590, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Dec 2020, 23 months.

Results were first posted in Feb 2021, 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2019
First posted
Jan 28, 2019
StartActual
Dec 27, 2018
Primary completionActual
Dec 11, 2020
CompletionActual
Dec 11, 2020
Results first posted
Feb 21, 2021
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03819218
Lead sponsor
MC2 Therapeutics
Responsible party
Sponsor
First posted
Jan 28, 2019
Start date
Dec 27, 2018
Primary completion
Dec 11, 2020
Completion
Dec 11, 2020
Results posted
Feb 21, 2021
Last update
Mar 19, 2021

Study contacts

Andreas Pinter, MD
principal investigator · Dept. of Dermatology, Venereology and Allergology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion